Copyright
©The Author(s) 2017.
World J Hepatol. Feb 18, 2017; 9(5): 270-277
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.270
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.270
Figure 1 Study design.
HVPG: Hepatic venous pressure gradient; HCC: Hepatocellular carcinoma.
Figure 2 General linear model comparing Pre (baseline), chronic (carvedilol at 3 mo) and post simvastatin haemodynamic parameters with respect to time in carvedilol responders and non-responders.
HR: Heart rate; MAP: Mean arterial pressure; FHVP: Free hepatic venous pressure; WHPG: Wedged hepatic venous pressure gradient; HVPG: Hepatic venous pressure gradient.
- Citation: Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9(5): 270-277
- URL: https://www.wjgnet.com/1948-5182/full/v9/i5/270.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i5.270